Nephroprotective Activity of Rutin in Diabetic Nephropathy Rat Model Targeting Nitric Oxide Pathway
The research conducted both In vitro and In vivo explored Rutin's impact on diabetic nephropathy, focusing on its effects on Nitric Oxide (NO) pathways in renal endothelial cells and in diabetic rats. In vitro, experiments using HRGECs revealed Rutin's ability to mitigate high glucose-induced cell death and reduced clearance of Bovine Serum Albumin on endothelial cells. Rutin's capacity for nitric oxide scavenging activity demonstrates its potential as an antioxidant. In the in vivo study, Rutin administration appeared to mitigate kidney damage induced by diabetes, as evidenced by reduced serum and urinary parameters associated with diabetic nephropathy. Moreover, the study observed a dose-dependent increase in nitrite/nitrate levels and collagen content in the kidneys. Histological abnormalities often refer to structural changes in tissues when examined under a microscope and high doses of Rutin might lead to an increase in the expression of eNOS in protective kidneys. This effect could be attributed to a decrease in the production of iNOS and nNOS protein levels. Rutin and L-Arginine hold promise as therapeutic avenues for addressing diabetic nephropathy, leveraging the nitric oxide pathway.